Caplin Point Labs Q4 Results: Net profit and revenue surge 19% each while margin expands to 34%

Caplin Point Laboratories reported a healthy set of earnings for the fourth quarter, supported by strong revenue growth and improved operating performance.

The company posted a net profit of ₹173 crore for Q4FY26, registering a 19% year-on-year increase from ₹145.3 crore reported in the corresponding quarter last year.

Revenue from operations rose 19.4% YoY to ₹600 crore, compared to ₹502.5 crore in Q4FY25, reflecting sustained demand across key markets and product segments.

At the operating level, EBITDA stood at ₹204.2 crore for the quarter, up 21.4% from ₹168 crore reported a year ago. EBITDA margin improved to 34% from 33.5% in the corresponding quarter last year, indicating better operational efficiency.

Alongside the quarterly results, the company also outlined its global expansion plans. Caplin Point said it intends to enter additional regulated markets including Canada, Australia, the Middle East and North Africa (MENA) region, Russia/CIS countries, as well as larger Latin American markets such as Mexico and Brazil over the near-to-medium term horizon.

The expansion strategy is expected to strengthen the company’s international footprint and diversify its revenue base across regulated and emerging pharmaceutical markets.

Pharma stocks have remained in focus amid increasing opportunities in regulated markets, product diversification and rising export demand from Indian drugmakers.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice.